Geron Corp GERN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
-
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
-
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
-
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
-
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
Trading Information
- Previous Close Price
- $1.23
- Day Range
- $1.19–1.25
- 52-Week Range
- $1.04–2.01
- Bid/Ask
- $1.22 / $1.25
- Shares Outstanding
- 642.47M
- Market Cap
- $777.39M
- Volume/Avg
- 464 / 10M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 258
- Website
- https://www.geron.com
Valuation
|
Metric
|
GERN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.54 |
Price/Sales | 3.94 |
Price/Cash Flow | — |
Price/Earnings
GERN
Financial Strength
|
Metric
|
GERN
|
|---|---|
Quick Ratio | 5.04 |
Current Ratio | 6.92 |
Interest Coverage | −1.72 |
Quick Ratio
GERN
Profitability
|
Metric
|
GERN
|
|---|---|
Return on Assets (Normalized) | −5.23% |
Return on Equity (Normalized) | −12.15% |
Return on Invested Capital (Normalized) | −3.68% |
Return on Assets
GERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!Z@#@Jt | LOCK|wNYz | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&lX%!xf | LOCK|H!c$! | $76B | |||
| Moderna Inc
MRNA
| LOCK|Y>fwzM | LOCK|Lg | $75B | |||
| argenx SE ADR
ARGX
| LOCK|?z!F#H | LOCK|P>X | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$Q>jw<v | LOCK|<y | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|mZ!SMFW | LOCK|pcX< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|mj>K!@& | LOCK|>?D^@ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|@<L@%@r | LOCK|%c | $24B | |||
| Incyte Corp
INCY
| LOCK|QXTB>b | LOCK|P# | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Hz!!&td | LOCK|@d | $15B |
United States